Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B GOTTLIEB

Showing results (341-350 of 523) with videos related to

Pageof 53
Sort By:
The Journal of Rheumatology|July 15, 2024
Report of the IDEOM Meeting Adjacent to the GRAPPA 2023 Annual MeetingGretchen D Ball, Danielle Yee, Arianna J Zhang, et al.
Journal of the American Academy of Dermatology|October 26, 2002
Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibodyAlice B Gottlieb, Mark Lebwohl, Mark C Totoritis, et al.
Journal of Clinical Pharmacology|February 11, 2005
Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasisDeborah L Mortensen, Patricia A Walicke, Xiaolin Wang, et al.
The Journal of Dermatological Treatment|September 14, 2007
Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) studyAlice B Gottlieb, Leon Kircik, Drore Eisen, et al.
Journal of the American Academy of Dermatology|January 15, 2017
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanerceptBruce Strober, Alice B Gottlieb, Bintu Sherif, et al.
The British Journal of Dermatology|March 8, 2022
Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritisKristian Reich, Xenophon Baraliakos, Laura C Coates, et al.
The Annals of Pharmacotherapy|May 13, 2004
FTY720 and cyclosporine: evaluation for a pharmacokinetic interactionJohn M Kovarik, Robert L Schmouder, Denise Barilla, et al.
The British Journal of Dermatology|May 13, 2005
Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trialS R Feldman, K B Gordon, M Bala, et al.
Arthritis Care & Research|August 3, 2016
Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic ArthritisProton Rahman, Lluis Puig, Alice B Gottlieb, et al.
Journal of the American Academy of Dermatology|November 14, 2006
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasisAlan Menter, Steven R Feldman, Gerald D Weinstein, et al.
Pageof 53

Showing results (341-350 of 523) with videos related to

Sort By:
Pageof 53
The Journal of Rheumatology|July 15, 2024
Report of the IDEOM Meeting Adjacent to the GRAPPA 2023 Annual MeetingGretchen D Ball, Danielle Yee, Arianna J Zhang, et al.
Journal of the American Academy of Dermatology|October 26, 2002
Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibodyAlice B Gottlieb, Mark Lebwohl, Mark C Totoritis, et al.
Journal of Clinical Pharmacology|February 11, 2005
Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasisDeborah L Mortensen, Patricia A Walicke, Xiaolin Wang, et al.
The Journal of Dermatological Treatment|September 14, 2007
Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) studyAlice B Gottlieb, Leon Kircik, Drore Eisen, et al.
Journal of the American Academy of Dermatology|January 15, 2017
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanerceptBruce Strober, Alice B Gottlieb, Bintu Sherif, et al.
The British Journal of Dermatology|March 8, 2022
Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritisKristian Reich, Xenophon Baraliakos, Laura C Coates, et al.
The Annals of Pharmacotherapy|May 13, 2004
FTY720 and cyclosporine: evaluation for a pharmacokinetic interactionJohn M Kovarik, Robert L Schmouder, Denise Barilla, et al.
The British Journal of Dermatology|May 13, 2005
Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trialS R Feldman, K B Gordon, M Bala, et al.
Arthritis Care & Research|August 3, 2016
Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic ArthritisProton Rahman, Lluis Puig, Alice B Gottlieb, et al.
Journal of the American Academy of Dermatology|November 14, 2006
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasisAlan Menter, Steven R Feldman, Gerald D Weinstein, et al.
Pageof 53